Introduction

MicroRNAs as regulators of gene expression
MicroRNAs (miRNAs) are single-strand, small non-proteincoding RNAs of 19 -25 nucleotides long highly conserved throughout different organisms. 1 The first miRNA was discovered in 1993 in Caenorhabditis elegans 2 but it took several years for the scientific community to become aware of the remarkable role that these small nucleotides have in the regulation of important processes, such as development, proliferation, differentiation, apoptosis and stress response. Although miRNA genes represent approximately 1% of the genome, 1 it has been estimated that more than 30% of genes are regulated by at least one miRNA. 3 The mature miRNAs are processed, after a complex but well established biogenesis, from a larger stem-loop precursor (pri-miRNA) (reviewed in Bartel 3 ) and negatively regulate gene expression at the post-transcriptional level. When mature miRNAs bind to the 3 0 -untranslated region (UTR) of the target mRNA with entire complementarity, the miRNA can lead to degradation of its target mRNA. However, in the vast majority of the miRNA-mRNA contacts, the mature miRNA is bound to the 3 0 -UTR region of its target mRNA with partial complementarity, in this case inducing a translational repression of its target gene 1, 3, 4 ( Figure 1 ). Interestingly, each miRNA can target and control the expression of several genes and each target mRNA may be regulated by various miRNAs, underscoring the role of the miRNAs in the regulation of critical biological functions. 3 miRNA expression patterns are regulated during development and differentiation of multiple tissues, 5 including the hematopoietic system, 6 -8 and have an important role in cell processes such as proliferation, apoptosis, differentiation and tumorigenesis. 9, 10 miRNAs and cancer
The first evidence of the involvement of miRNAs in human cancer was described by Calin et al.
11 in B-cell chronic lymphocytic leukemia, showing that these patients had deletions of chromosome 13q14 in 65% of them, a locus that included the mir-15a and mir-16-1 genes, which consequently presented downregulated expression. In another study, it was demonstrated that miRNA expression profiles of relatively few miRNAs (around 200 genes) was able to accurately classify human cancers, unlike expression profiles of about 16 000 protein-coding mRNA genes that were unable to group tumors in a coherent manner, 12 thus suggesting that miRNA signatures within tumors reflect their developmental history, a hypothesis that is compatible with the evidence that miRNAs direct tissuespecific developmental functions.
Over half of the sequence of mapped miRNAs are frequently located in human cancer associated genomic regions 13 and several studies have shown that miRNA expression is frequently deregulated in human tumors, including hematological malignancies. miRNAs can contribute to the development of cancer either as oncogenes (oncomirs) when tumor-suppressor genes (TSGs) are targeted, or as TSGs, when instead oncogenes are targeted. 4,11,14 -17 Aberrant miRNA profiling has been described in most cancers, and remarkably as a general rule the global miRNA expression profile is decreased in comparison with normal tissues. 4 Furthermore, a large number of studies have demonstrated that certain miRNAs have a causal role in tumorigenesis depending on the targets they regulate. 18 -25 Besides their oncogenic role, miRNAs can also be used as biomarkers for diagnosis and prognosis of various cancers 15,26 -29 and even to define the response to different drugs used in the treatment of human tumors. 30 -32 Although hundreds of miRNAs have been discovered and their functions have been intensively studied in human tumors, the mechanisms that control their expression are largely unknown. It is now accepted that miRNA expression can be affected by the same mechanism modulating protein-coding genes, including genetic mechanisms such as mutation, 33 deletion, 11,33 -35 Figure 1 ).
Epigenetic regulation of gene expression and cancer
Epigenetic mechanisms are refereed to heritable changes in gene expression that occur in a cell without changes in their genomic sequence. 43 The two most widely studied epigenetic mechanisms are DNA methylation and histone modification. DNA methylation occurs mainly in the cytosine located in a CpG dinucleotide. This CpG is underrepresented in the genome, except for small regions known as CpG islands. 44 Most CpG islands are located in the proximal promoter regions of almost half of the genes and are usually unmethylated in normal cells. By contrast, in tumor cells, the promoter hypermethylation of these areas is the most common epigenetic aberration, being associated with the inappropriate transcriptional silencing of these genes. 45 -48 In addition to inappropriate methylation, repression of the expression of specific genes is often accompanied by modifications in the amino terminal coils of histones. Regulation of gene expression can occur through post-translational modifications of the histone tails, including covalent changes, such as acetylation, methylation, phosphorylation, ubiquitination, sumoylation, proline isomerisation, and ADP-ribosylation that constitute what is known as histone code. In tumor cells, chromatin conformation is usually altered by histone modifications that confer a close chromatin conformation by reducing the expression of marks of open chromatin (for example, acetylation of histone 3 and 4 (AcH3 and AcH4) and the trimethylation of lysine 4 of histone 3 (3mK4H3)) or increasing the expression of close chromatin marks (trimethylation of lysine 9 and lysine 27 of the histone 3 (3mK9H3 and 3mK27H3)). 49, 50 Importantly, DNA methylation and histone modifications are epigenetic events that work together, so that it is the complex interplay of posttranslational modifications of specific residues on histone tails coupled with the DNA methylation status at a particular locus that determines whether a particular gene may be transcriptionally active or repressed. 51 The role of aberrant epigenetic modifications in acute leukemias has clearly been recognized during recent years, 52 -61 and these include the deregulation of miRNAs. 14, 62, 63 Moreover, it has been observed that the miRNA expression signatures can discriminate acute lymphoblastic leukemia (ALL) from acute myeloid leukemia (AML), 15 including the different genetic subentities within each leukemia subgroup. 64 -68 Although the specific role of the miRNAs in the regulation of gene expression and the development of leukemias are addressed in other reviews of the current spotlight series and have also been discussed recently, 65 we will focus on (i) the role of epigenetic mechanisms in the regulation of miRNAs in acute leukemias; (ii) how these mechanisms may contribute to the development of the disease; and (iii) the identification of miRNAs as new biomarkers and potential therapeutic targets.
Epigenetically regulated miRNAs in ALL
Epigenetic regulation of miRNAs as a prognostic factor in ALL Aberrant epigenetic regulation, particularly DNA hypermethylation of gene promoters, is a frequent mechanism of gene silencing that has been associated with the prognosis of the disease and response to therapy in patients with B-cell precursor ALL (B-ALL). 52 -57,69,70 Interestingly, an extensive analysis of genomic sequences of miRNA genes has shown that around half of them are associated with CpG islands, suggesting that they could be subject to this mechanism of regulation. 71 Indeed, aberrant methylation of miRNAs has been demonstrated in patients with ALL (Table 1 ). Using ALL cell lines, our group demonstrated that 13 miRNAs were regulated both by hypermethylation and histone modifications associated with a close chromatin conformation (decrease of 3mK4H3 and/or increase of 2mK9H3) of 11 CpG islands that were embedded or closed to these miRNAs (hsa-miR-9 -1, hsa-miR-9 -2, hsa-miR-9 -3, hsa-miR-10b, hsa-miR-34b, hsa-miR-34c, hsa-miR-124a1, hsa-miR-124a2, hsa-miR-124a3, hsa-miR-132, hsa-miR-196b, hsa-miR-203 and hsa-miR-212). 72 When the analysis was performed using bone marrow samples from 353 ALL patients at diagnosis, hypermethylation of at least one of the 13 miRNAs (methylated group) was found in 65% of the cases. Methylation was associated with downregulation of miRNA expression, which could be reverted by treatment with demethylating agents such as 5 -Aza-2 0 -deoxycytidine, suggesting that expression of Epigenetic regulation of miRNA genes X Agirre et al 396 these miRNAs was regulated by epigenetic changes. 72 Patients that belonged to the methylated group showed a significantly higher relapse and mortality rate, and on the multivariate analysis, miRNA hypermethylation was an independent adverse prognostic factor for disease free survival and overall survival. The separate analysis of children and adult patients provided similar results, suggesting that the prognostic value of hypermethylation is independent of age in ALL. Another interesting finding was that the methylation profile was able to redefine the prognosis for some ALL genetic sub-groups: the initial good prognosis of pediatric TEL-AML1-positive ALL patients was significantly worsened in those patients with at least one of the 13 miRNAs methylated and in contrast, the expected poor outcome in BCR-ABL1-positive or high-WBC-count ALL patients was significantly improved in patients without miRNA hypermethylation. 72 In addition, the methylation pattern of miRNAs has a clear impact on the prognosis of patients with ALL undergoing stem cell transplantation. 73 These studies indicate that aberrant hypermethylation of miRNAs in ALL may help to predict clinical outcome and might eventually lead to the establishment of risk-adapted therapies.
Epigenetically controlled miRNAs regulate pathways implicated in tumorigenesis
Intriguingly, the family of the hsa-miR-9 and the hsa-miR-124a are encoded by three different loci in each case located in different chromosomal regions (hsa-miR-124a-1 at 8p23.1, hsamiR-124a-2 at 8q212.3 and hsa-miR-124a-3 at 20q13.33, hsamiR-9 -1 at 1q22, hsa-miR-9 -2 at 5q14.3 and hsa-miR-9 -3 at 15q26.1). Detection of aberrant methylation of three independent loci that encode the same gene supports the role of these miRNAs in the pathogenesis of ALL. Furthermore, in both cases, the inappropriate methylation of miRNAs was associated with decrease or complete lack of expression of the mature miRNA, whereas forced re-expression of miRNAs was associated with inhibition of leukemic cell proliferation and in some cases increased apoptosis. 74, 75 These experiments suggest that directly Abbreviations: ALL, acute lymphoblastic leukemia; miRNAs, microRNAs; MLL, histone-lysine N-methyltransferase.
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Epigenetic regulation of miRNA genes X Agirre et al 397 or indirectly, hsa-miR-9 and the hsa-miR-124a regulate pathways implicated in the pathogenesis of ALL. Although evidence for the deregulation of FGFR1 by hsa-miR-9 is limited, 75 several studies have shown that regulation of the CDK6-RB1 pathway is mediated by a number of miRNAs, including the hsa-miR124a, 74 not only in leukemia but also in other hematological malignancies such as myeloma and lymphoma.
76 CDK6 is also a target of hsa-miR-34b and hsa-miR-34c, inappropriately methylated in 35% of ALL cases. 72, 77 These results highlight the fact that CDK6-RB1 pathway may be a preferred target of aberrantly methylated miRNAs in ALL, establishing this pathway as an attractive therapeutic target in these disorders.
Recent studies have shown that members of miR-34 family, hsa-miR-34a, hsa-miR-34b and hsa-miR-34c, are direct targets of the TSG P53, which is involved in cell cycle arrest and induction of apoptosis in tumor cells. 78 -82 TP53 is one of the genes most frequently mutated in human cancer, with inactivating mutations present in over 50% of patients with solid tumors. This percentage is much lower in hematological malignancies, with less than 3% of patients with ALL showing mutations of TP53, despite the fact that ALL cells present an abnormal resistance to apoptosis, a hallmark of deregulated p53 pathway. 83 Aberrant hypermethylation of hsa-miR-34a has been detected in various hematological malignancies such as B-cell chronic lymphocytic leukemia, multiple myeloma and lymphomas, but not in samples from patients with ALL. 84 Conversely, we found that hsa-miR-34b and hsa-miR-34c were hypermethylated in 35% of ALL patient samples, 77 along with other genes implicated in the regulation of the P53 pathway, suggesting that aberrant miRNA expression due to inappropriate methylation could result in the deregulation of the TSG TP53.
The most common cytogenetic abnormalities in ALL are chromosomal translocations such as BCR-ABL1 t(9;22), TEL-AML1 t(12;21), histone-lysine N-methyltransferase (MLL)-AF4 t(4;11), among others. These translocations (1) usually activate and deregulate transcription factors involved in the control of cell differentiation, proliferation and apoptosis, and consequently are responsible for the impairment of normal cellular behavior, 85 and (2) identify unique subtypes of the disease that associate specific prognosis and therapeutic responses. 86 -88 Several studies have shown that genes involved in these chromosomal translocations may be regulated by miRNAs and vice versa, some miRNAs may be regulated by these genes. In addition, some of these miRNAs are deregulated because of aberrant methylation in ALL. This is the case of the ABL1 and the fusion oncoprotein BCR-ABL1, a hallmark of chronic myelogenous leukemia and some cases of Ph þ B-ALL. 89 Both ABL1 and the BCR -ABL1 fusion gene are relevant targets for the miRNA hsa-miR-203. 90 Hsa-miR-203 is aberrantly methylated in ALL, 72, 91 suggesting that silencing of this miRNA may provide a proliferate advantage in BCR-ABL1-positive leukemia or in leukemia with higher levels of ABL1 and that restoration of its expression can be a useful treatment for these patients.
MLL-rearranged ALL is a high-risk type of childhood leukemia with a dismal prognosis in infants. 92 Recent studies have demonstrated that distinct promoter CpG island methylation patterns separate different genetic subtypes of MLL-rearranged ALL in infants and that the degree of promoter hypermethylation among infant ALL patients appeared to influence relapse-free survival. 55 The same group of investigators identified 11 miRNAs that were downregulated in t(4;11)-positive infant ALL as a consequence of CpG hypermethylation, seven of which (hsa-miR-10a, hsa-miR-152, hsa-mir-200a, hsa-miR-220b, hsa-miR-429, hsa-miR-432 and hsa-miR-503) were re-expressed after treatment with the DNA methyltransferase inhibitor Zebularine. 93 Interestingly, five of these miRNAs are associated either with MLL or MLL fusions. The expression of putative targets of hsa-miR-10a, such as HOXA3 is elevated in MLL-rearranged infant ALL patients. ZEB2, a validated target of miR-220b/a-429 cluster and highly expressed in t(4;11) positive ALL cells, was decreased after treatment with demethylating agent with an increase in expression of hsa-miR-220b. Finally, the same treatment led to upregulation of hsa-miR-152 and downregulation of DNMT1 and MLL. Interestingly, heavily methylated patients presented a higher methylation of hsa-miR-152, therefore suggesting that the level of hsa-miR-152 methylation and DNMT1 expression may determine the severity of methylation profile and the increased risk of relapse and reduced overall survival observed in patients with methylation of this miRNA. 93 Along the same lines, Dou et al. 94 showed that the fusion protein MLL-AF4 is regulated by hsa-miR-143. This miRNA is aberrantly and preferentially methylated in MLL-AF4-positive ALL cells and its re-expression induces apoptosis and inhibits proliferation of leukemic cells, indicating that inhibition of hsa-miR-143 expression due to inappropriate methylation provides a proliferative advantage to MLL-AF4-positive ALL cells and restoration of this miRNA maybe a beneficial treatment for these patients.
It has also been shown that MLL and MLL fusion proteins, in addition to being regulated by miRNAs, can directly regulate the expression of these small non-coding RNAs. This is the case for hsa-miR-196b, whose expression was found to be upregulated in ALL cells with MLL rearrangements and T-ALL due at least in part to reduced DNA methylation at CpG islands in the promoter regions of hsa-miR-196b. Expression of hsa-miR-196b was also found in patients with T-cell ALL patients carrying CALM-AF10, SET-NUP214 and inversion of chromosome 7 and in both cases these abnormalities were functionally linked with upregulation of HOXA, 95 suggesting co-activation of miR-196b and HOXA genes in ALL. In contrast to these results, this miRNA has been detected as being aberrantly methylated and downregulated in ALL patient samples, having as one of the potential putative targets the oncogene MYC. 72, 96 The upregulation of another 31 miRNAs after treatment of ALL-derived NALM-6 cell line with the histone deacetylase (HDAC) inhibitor trichostatin A has been described. 97 As in the case of hsa-miR-124a, 74 these miRNAs could be repressed by aberrant histone modifications associated with closed chromatin structure. Interestingly, in the case of hsa-miR-22, its transcriptional repression was associated with an increase in trimethylation of lysine 27 of histone 3 (3mK27H3) without aberrant DNA methylation around the transcriptional start point of the miRNA. 97 The repressive 3mK27H3 mark is catalyzed by polycomb repressive complex 2 (PRC2), which is formed by EZH2 (methyltransferase catalytic subunit of the PRC2 complex), SUZ12 and EED. 98, 99 Recent reports have shown that PRC2 proteins maintains a 'bivalent' chromatin state expressing both histone modification marks of open (3mK4H3) and closed (3mK27H3) chromatin in embryonic stem cells , indicating that such polycomb target genes are predisposed for cancer-specific hypermethylation. This phenomenon has been shown for several tumors such as breast, colon cancer, lymphoma and ALL.
77,100 -102 Surprisingly, it has been reported that several miRNAs inappropriately methylated in ALL are targets of SUZ12, and that their decreased expression is restored by inhibiting EZH2 expression (Table 1) . 103 These miRNAs, in turn, regulate the expression of PRC1 proteins BMI1 and RING2, which establish a coordinate regulation of PRC1 and PRC2 activities mediated by miRNAs. 103, 104 These results may also indicate that inappropriate epigenetic regulation of miRNAs
could be the initial event that predisposes a precursor ALL cell for transformation or, alternatively, that the common genetic changes in ALL (such as chromosomal translocations) are the initial transformation event that leads ALL cells to a more undifferentiated stage that acquires the epigenetic changes. In this regard, future studies will be needed to better define the role of the epigenetic regulation of miRNAs in the development of ALL.
Epigenetically regulated miRNAs in AML
A number of studies have demonstrated miRNAs to be differentially expressed in AML in comparison with their normal counterparts and have further defined miRNA expression profiles associated with cytogenetic AML subtype, molecular subgroups and prognosis in AML. 105 -109 Unlike the case with ALL, the mechanisms of de-regulation of these miRNAs in AML are mostly unknown, although some are shared by ALL such as the decreased expression of certain miRNAs that has been associated with alterations in epigenetic mechanisms, defining them as directly responsible for miRNAs regulation ( Table 2 ).
The inappropriate methylation of two of the three members of the family of miRNA hsa-miR-124a (hsa-miR-124a-1 and hsamiR-124a-3) has been found in cell lines and AML patient samples independently of the cytogenetic subtype. 76, 110, 111 Epigenetic silencing of hsa-miR-124a was associated with EVI1 expression, 110,112 a zinc-finger transcription factor overexpressed and implicated in the development and progression of AML. 113 -116 As demonstrated in other solid and hematological tumors, 22, 74, 117 CDK6 is also regulated by hsa-miR-124a in AML cells. 111 Treatment of AML cells with the CDK6 inhibitor PD0332991 inhibits their growth, and offers a new alternative for future treatment of patients with AML. 110 In AML cells, hsa-miR-124a directly interacts with the 3 0 -UTR of CEBPA and negatively regulates its protein levels. 111 CEBPA is a key transcription factor involved in regulation of myeloid differentiation and granulocytic maturation. 118 Loss of function of CEBPA is associated with a blockage of granulopoiesis and has an important role in AML transformation, 119 providing an additional role of the hsa-miR-124a in the pathogenesis of AML. CEBPA positively regulates the expression of hsa-miR-223, which in turn leads to E2F1 repression and inhibition of cellcycle progression resulting in myeloid differentiation, 120 whereas overexpressed E2F1 binds to hsa-miR-223 promoter and inhibits hsa-miR-223 transcription through a negative feedback loop resulting in myeloid cell-cycle progression and blocking of differentiation. Although CEBPA 111 is silenced because of promoter hypermethylation in AML, a mechanism for hsa-miR-223 transcription suppression has been reported in AML patients with the t(8;21) translocation. 121 AML/ETO is the most common AML-associated fusion protein and a recent study has demonstrated that hsa-miR-223 is a direct transcriptional target of AML1/ETO. 122 By recruiting chromatin-remodeling enzymes at an AML1-binding site on the pre-miR-223 gene, AML1/ETO induces heterochromatic silencing of hsa-miR-223. Ectopic hsa-miR-223 expression, RNAi against AML1/ETO, or demethylating treatment enhances hsa-miR-223 levels and restores cell differentiation. This study identifies an additional action for a leukemia fusion protein and establishes a link between epigenetic silencing of a miRNA locus and the pathogenesis of AML Mutations in the proto-oncogene cKIT are a frequent genetic alteration in AML and have been observed in 40% of patients with either the inv(16) or t (8;21) . The presence of these mutations is associated with poor outcome at least in adult patients. 123, 124 Gao et al. 125 showed that 6 miRNAs (hsa-miR-137, hsa-miR-193a, hsa-miR-193b, hsa-miR-218, hsa-miR-221 and hsa-miR-222) bind to the 3 0 -UTR region and negatively regulate cKIT. Of these 6 miRNAs, hsa-miR-193a was downregulated because of inappropriate methylation of its promoter region in both cell lines and primary samples from patients with AML. Hsa-miR-193a expression was inversely correlated with cKIT expression and overexpression of hsa-miR-193a reduced cell growth and induced apoptosis and differentiation of AML cells. These data further strengthen the role for methylation-repressed miRNA in myeloid leukemogenesis.
Another epigenetically regulated miRNA implicated in the pathogenesis of AML is the hsa-miR34b. This miRNA regulates cyclic AMP responsive element-binding protein (CREB), a welldescribed proto-oncogene involved in the pathogenesis of AML, which is downregulated in patients with AML owing to aberrant hypermethylation. 77 In a recent study, Pigazzi et al. 126, 127 demonstrate that the hsa-miR34b directly interacted with the CREB 3 0 -untranslated region, with the consequent reduction of the CREB protein levels in vitro. Interestingly, the forced expression of hsa-miR-34b or CREB silencing in AML cells caused cell cycle abnormalities, reduced anchorage-independent growth and suppressed the myeloid cell growth, suggesting that the CREB protein regulation by hsa-miR-34b is an important mechanism in tumor regulation in AML. 127 The analysis of the methylation status of another member of the family of miRNA-34, namely hsa-miR-34a, in 20 samples from patients with AML showed that aberrant methylation of hsa-miR-34a was significantly more frequent in lymphoid than myeloid malignancies. 84 The same authors found similar results in terms of inappropriate methylation of hsa-miR-203. Although in this case, methylation of hsa-miR-203 was positive in 10% of AML cases, the presence of epigenetic alterations was significantly more frequent in lymphoid hematological malignancies. Table 2 Epigenetically regulated miRNAs in AML Abbreviations: AML, acute myeloid leukemia; miRNAs, microRNAs.
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Overall, the methylation of miRNAs is found in a lower percentage of patients with AML in comparison with those with ALL (Tables 1 and 2 ). In addition, disruption of other epigenetic mechanism also seems to be less frequent in AML. 61 Nevertheless, although inappropriate methylation is observed in a smaller number of miRNAs in AML, most of them are targets of the Polycomb group (Table 2) . 103, 104 These results suggest that inappropriate epigenetic regulation of miRNAs may have an important role in the maintenance of the undifferentiated state of myeloid cells in AML.
Concluding remarks
In this review we have tried to summarize our current view of the role of epigenetic regulation of miRNAs in the pathogenesis of acute leukemias. miRNAs represent another level of regulation of gene expression that, like other 'classical' genes, may be regulated by epigenetic mechanisms, DNA methylation and histone modifications. In leukemia, miRNAs are frequently deregulated by genetic and epigenetic mechanisms and this abnormal expression participates in leukemogenesis either directly (functioning as TSGs) or indirectly by interfering with the expression and function of TSGs or oncogenes. As the final aim of translational research should be to translate the biological findings into the clinical application, the current challenge is to determine how to exploit this knowledge to improve the treatment of patients with leukemia. From the evidence discussed we would envision three different applications of miRNAs: (1) as biomarkers: the presence of abnormally methylated miRNAs, miRNA expression profiles or expression or lack of specific miRNAs should help in the risk assessment and the design of personalized therapies for patients with leukemia. Large series of patients and prospective validation will be required to fulfill this goal; (2) as therapeutic targets: epigenetic silencing of miRNAs is involved in the regulation of key pathways involved in leukemogenesis, therefore the use of epigenetic drugs able to induced re-expression of these miRNAs alone or in combination with standard chemotherapy could provide a therapeutic advantage for these patients. In that sense, de-methylating agents or inhibitors of histone de-acetylases have already been used in myeloid malignancies with promising results; (3) as therapeutic molecules: miRNAs could be used to either directly regulate gene expression, for instance by modulating the levels of oncogenes and TSGs, or to control the epigenetic machinery targeting the effector enzymes such as DNMT, HDAC or polycomb complex proteins. In summary, the discovery and understanding of the biology of miRNAs has unveiled a new level of gene regulation that certainly offers new promise for the treatment of patients with lymphoid and myeloid leukemias.
